Tenax pauses LEVEL-2 trial, refines enrollment based on Phase 3 results

Tenax temporarily paused enrollment in its LEVEL-2 clinical trial for TNX-103 and plans to amend enrollment criteria based on learnings from the recently completed Phase 3 LEVEL trial in PH-HFpEF. The company has also requested a Type C meeting with the FDA to discuss levosimendan development. This represents a trial strategy adjustment with potential regulatory dialogue, but lacks clarity on trial outcomes or FDA guidance impact.

A drug developer paused its Phase 2 trial to refine who it enrolls based on earlier results, and is meeting with the FDA to discuss its program. This is operational news about trial strategy rather than a definitive clinical outcome or regulatory decision.